TMS Co., Ltd.
Research TMS Co., Ltd. (4891.T) on Bullrun: market cap JPY 5.51B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4891.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 5.51B
- Financial periodFY2025
- RevenueJPY 0
- Net income-JPY 660.55M
- Free cash flow-JPY 524.60M
Valuation Snapshot
latest market cap is JPY 5.51B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | JPY 0 | -JPY 660.55M | -JPY 524.60M | n/a | n/a | JPY 2.92B | n/a | JPY 2.82B |
| FY2024 | JPY 0 | -JPY 960.04M | -JPY 826.17M | n/a | -26.02 | JPY 3.45B | n/a | JPY 3.46B |
| FY2023 | JPY 0 | -JPY 860.93M | -JPY 702.14M | n/a | -25.28 | JPY 3.58B | n/a | JPY 3.71B |
| FY2022 | JPY 1.95B | JPY 1.08B | JPY 1.25B | n/a | 53.36 | JPY 2.60B | n/a | JPY 2.45B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 5.51B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About TMS Co., Ltd.
TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is TMS Co., Ltd.'s market cap?
TMS Co., Ltd.'s market capitalization is JPY 5.51B.
What does TMS Co., Ltd. do?
TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia.